Long-term serotonin effects in the rat are prevented by terguride

Regulatory Peptides

Volumn 143, Issue 1-3, 2007, Pages 39-46

  Hauso, Øyvind ^a,b   Gustafsson, Björn I ^a,b   Loennechen, Jan P ^a,b   Stunes, Astrid K ^a   Nordrum, Ivar ^a,b   Waldum, Helge L ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Carcinoid heart disease; Proliferation; Receptors; Serotonin; Skin; Terguride

Indexed keywords

ERGOLINE DERIVATIVE; SEROTONIN; SEROTONIN 2B RECEPTOR; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR; TERGURIDE;

ACANTHOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA VALVE REGURGITATION; ARTICLE; CARCINOID SYNDROME; CELL PROLIFERATION; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART WEIGHT; INJECTION SITE REACTION; KERATOSIS; LIVER WEIGHT; LUNG INSUFFICIENCY; MESENCHYME CELL; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONINERGIC SYSTEM; STOMACH;

3T3 CELLS; ANIMALS; CARCINOID HEART DISEASE; CELL PROLIFERATION; ECHOCARDIOGRAPHY; EPIDERMIS; FEMALE; HEART; INJECTIONS, SUBCUTANEOUS; LISURIDE; MICE; MYOCARDIUM; ORGAN SIZE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SKIN; STOMACH;

ANIMALIA; RATTUS;

EID: 34547687436     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2007.02.009     Document Type: Article

References (39)

1. Hoyer D., Hannon J.P., and Martin G.R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71 (2002) 533-554
2. Nemecek G.M., Coughlin S.R., Handley D.A., and Moskowitz M.A. Stimulation of aortic smooth muscle cell mitogenesis by serotonin. Proc Natl Acad Sci U S A 83 (1986) 674-678
3. Westbroek I., van der Plas A., de Rooij K.E., Klein-Nulend J., and Nijweide P.J. Expression of serotonin receptors in bone. J Biol Chem 276 (2001) 28961-28968
4. Gustafsson B.I., Thommesen L., Stunes A.K., Tommeras K., Westbroek I., Waldum H.L., et al. Serotonin and fluoxetine modulate bone cell function in vitro. J Cell Biochem 98 (2006) 139-151
5. Takuwa N., Ganz M., Takuwa Y., Sterzel R.B., and Rasmussen H. Studies of the mitogenic effect of serotonin in rat renal mesangial cells. Am J Physiol 257 (1989) F431-F439
6. Seuwen K., Magnaldo I., and Pouysségur J. Serotonin stimulates DNA synthesis in fibroblasts acting through 5-HT1B receptors coupled to a Gi-protein. Nature 335 (1988) 254-256
7. Pakala R., Willerson J.T., and Benedict C.R. Mitogenic effect of serotonin on vascular endothelial cells. Circulation 90 (1994) 1919-1926
8. Lesurtel M., Graf R., Aleil B., Walther D.J., Tian Y., Jochum W., Grachet C., Bader M., and Clavien P.A. Platelet-derived serotonin mediates liver regeneration. Science 312 (2006) 104-107
9. Gustafsson B.I., Tømmerås K., Nordrum I., Loennechen J.P., Brunsvik A., Solligård E., Fossmark R., Bakke I., Syversen U., and Waldum H. Long-term serotonin administration induces heart valve disease in rats. Circulation 111 (2005) 1517-1522
10. Fitzgerald L.W., Burn T.C., Brown B.S., Patterson J.P., Corjay M.H., Valentine P.A., Sun J.H., and Robertson D.W. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 57 (2000) 75-81
11. Slominski A., Pisarchik A., Zbytek B., Tobin D.J., Kauser S., and Wortsman J. Functional activity of serotoninergic and melatoninergic systems expressed in the skin. J Cell Physiol 196 (2003) 144-153
12. Connolly H.M., Crary J.L., McGoon M.D., Hensrud D.D., Edwards B.S., Edwards W.D., and Schaff H.V. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337 (1997) 581-588
13. Van Camp G., Flamez A., Cosyns B., Weytjens C., Muyldermans L., Van Zandijcke M., De Sutter J., Santens P., Decoodt P., Moeman C., and Schoors D. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 363 (2004) 1179-1183
14. Serratrice J., Disdier P., Habib G., Viallet F., and Weiller P.J. Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev 10 (2002) 334-336
15. Horvath J., Fross R.D., Kleiner-Fisman G., Lerch R., Stalder H., Liaudat S., Raskoff W.J., Flachsbart K.D., Rakowski H., Pache J.C., Buckhard P.R., and Lang A.E. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 19 (2004) 656-662
16. Jähnichen S., Horowski R., and Pertz H.H. Agonism at 5-HT2B receptors is not a class effect of the ergolines. Eur J Pharmacol 513 (2005) 225-228
17. Newman-Tancredi A., Cussac D., Quentric Y., Touzard M., Verrièle L., Carpentier N., and Millan M.J. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. J Pharmacol Exp Ther 303 (2002) 815-822
18. Litwin S.E., Katz S.E., Morgan J.P., and Douglas P.S. Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. Circulation 89 (1994) 345-354
19. Loennechen J.P., Wisløff U., Falck G., and Ellingsen O. Effects of cariporide and losartan on hypertrophy, calcium transients, contractility, and gene expression in congestive heart failure. Circulation 105 (2002) 1380-1386
20. Fornoni A., Cornacchia F., Howard G.A., Roos B.A., Striker G.E., and Striker L.J. Cyclosporin A affects extracellular matrix synthesis and degradation by mouse MC3T3-E1 osteoblasts in vitro. Nephrol Dial Transplant 16 (2001) 500-505
21. Rascol O., Pathak A., Bagheri H., and Montastruc J.L. Dopaminagonists and fibrotic valvular heart disease: further considerations. Mov Disord 19 (2004) 1524-1525
22. Martin K.B., Klinger J.R., and Rounds S.I. Pulmonary arterial hypertension: new insights and new hope. Respirology 11 (2006) 6-17
23. Polakowski J.S., Segreti J.A., Cox B.F., Hsieh G.C., Kolasa T., Moreland R.B., and Brioni D.J. Effects of selective dopamine receptor subtype agonists on cardiac contractility and regional haemodynamics in rats. Clin Exp Pharmacol Physiol 31 (2004) 837-841
24. Robertson J.I. Carcinoid syndrome and serotonin: therapeutic effects of ketanserin. Cardiovasc Drugs Ther 4 Suppl 1 (1990) 53-58
25. Smith B.M., Thomsen W.J., and Grottick A.J. The potential use of selective 5-HT2C agonists in treating obesity. Expert Opin Invest Drugs 15 (2006) 257-266
26. Miller K.J. Serotonin 5-ht2c receptor agonists: potential for the treatment of obesity. Mol Interv 5 (2005) 282-291
27. Slominski A., Pisarchik A., Semak I., Sweatman T., Wortsman J., Szczesniewski A., Slugocki G., McNulty J., Kauser S., Tobin D.J., Jing C., and Johansson O. Serotoninergic and melatoninergic systems are fully expressed in human skin. FASEB J 16 (2002) 896-898
28. Slominski A., Pisarchik A., Semak I., Sweatman T., Szczesniewski A., and Wortsman J. Serotoninergic system in hamster skin. J Invest Dermatol 119 (2002) 934-942
29. Slominski A., Pisarchik A., Johansson O., Jing C., Semak I., Slugocki G., and Wortsman J. Tryptophan hydroxylase expression in human skin cells. Biochim Biophys Acta 1639 (2003) 80-86
30. Lundeberg L., El-Nour H., Mohabbati S., Morales M., Azmitia E., and Nordlind K. Expression of serotonin receptors in allergic contact eczematous human skin. Arch Dermatol Res 294 (2002) 393-398
31. Slominski A., Wortsman J., and Tobin D.J. The cutaneous serotoninergic/melatoninergic system: securing a place under the sun. FASEB J 19 (2005) 176-194
32. Huang J., Li G., Xiang J., Yin D., and Chi R. Immunohistochemical study of serotonin in lesions of chronic eczema. Int J Dermatol 43 (2004) 723-726
33. Huang J., Li G., Xiang J., Yin D., and Chi R. Immunohistochemical study of serotonin in lesions of psoriasis. Int J Dermatol 43 (2004) 408-411
34. Stratz T., and Müller W. Treatment of systemic sclerosis with the 5-HT3 receptor antagonist tropisetron. Scand J Rheumatol Suppl 119 (2004) 59-62
35. Kato S., Kishiro I., Ohnuma N., Takasaki K., Okamoto S., Nakamoto A., Kaneko N., and Kumamoto H. Suppressive effect of saprogrelate hydrochloride on Raynaud's phenomenon and respiratory failure in patients with systemic sclerosis. Respirology 5 (2000) 27-32
36. Bell H.K., Poston G.J., Vora J., and Wilson N.J. Cutaneous manifestations of the malignant carcinoid syndrome. Br J Dermatol 152 (2005) 71-75
37. Maurer M., Opitz M., Henz B.M., and Paus R. The mast cell products histamine and serotonin stimulate and TNF-alpha inhibits the proliferation of murine epidermal keratinocytes in situ. J Dermatol Sci 16 (1997) 79-84
38. Fuziwara S., Suzuki A., Inoue K., and Denda M. Dopamine D2-like receptor agonists accelerate barrier repair and inhibit the epidermal hyperplasia induced by barrier disruption. J Invest Dermatol 125 (2005) 783-789
39. Nojima H., and Carstens E. 5-Hydroxytryptamine (5-HT)2 receptor involvement in acute 5-HT-evoked scratching but not in allergic pruritus induced by dinitrofluorobenzene in rats. J Pharmacol Exp Ther 306 (2003) 245-252